GlobeNewswire
Genmab Announces Preclinical Information to be Introduced at American Affiliation for Most cancers Exploration (AACR) Annual Meeting 2021
Media Release Copenhagen, Denmark, March 10, 2021 ·Two posters that includes modern Genmab bispecific antibody programs picked for presentation at AACR Once-a-year Assembly 2021 Genmab A/S (Nasdaq: GMAB) announced today that two posters analyzing investigational medicines designed using Genmab’s DuoBody® technologies will be introduced at the American Affiliation for Most cancers Research Annual Assembly 2021, having location nearly April 10-15 and Could 17-21. The posters summarize data from a preclinical evaluation of the investigational medication, epcoritamab (DuoBody-CD3xCD20) in blend with conventional of treatment therapies for the treatment of B-mobile lymphomas, and a preclinical system of action evaluation of GEN1042 (DuoBody-CD40x4-1BB). The abstracts have been revealed on the AACR site and may possibly be accessed by using the On the net Meeting Planner. All e-poster shows will be built available on the on-desire Virtual Congress system on www.aacr.org. Epcoritamab is currently being co-created by Genmab and AbbVie. GEN1042 is being co-formulated by Genmab and BioNTech. “We are excited to existing facts showcasing the progress we are building with crucial investigational medications in our item pipeline making use of the innovative DuoBody bispecific antibody platform,” explained Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “Together with our companions, we proceed to make use of the DuoBody engineering platform to proficiently make possibilities for ground breaking antibody drug structure and progress with the target of transforming most cancers procedure.” Epcoritamab (DuoBody-CD3xCD20):Preclinical evaluation of epcoritamab combined with typical of treatment therapies for the treatment of B-mobile lymphomas GEN1042 (DuoBody-CD40x4-1BB): DuoBody-CD40x4-1BB (GEN1042) induces dendritic-mobile maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist action About Epcoritamab Epcoritamab is an investigational IgG1-bispecific antibody designed working with Genmab’s proprietary DuoBody technologies. Genmab’s DuoBody-CD3 technologies is created to immediate cytotoxic T cells selectively to tumors to elicit an immune reaction towards malignant cells. Epcoritamab is intended to concurrently bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells.1 CD20 is a clinically validated therapeutic concentrate on, and is expressed on several B-cell malignancies, together with diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and serious lymphocytic leukemia.2,3 Epcoritamab is getting co-made by Genmab and AbbVie as aspect of the companies’ wide oncology collaboration. About GEN1042 (DuoBody-CD40x4-1BB)GEN1042 (DuoBody-CD40x4-1BB) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, developed applying Genmab’s DuoBody technologies. It is currently being co-produced beneath an arrangement in which the corporations share all fees and potential gains for the solution on a 50:50 basis. CD40 and 4-1BB had been picked as targets to improve equally dendritic cells (DC) and antigen-dependent T-mobile activation, working with an inert DuoBody structure. About Genmab Genmab is an intercontinental biotechnology enterprise with a main objective to improve the lives of sufferers with most cancers. Founded in 1999, Genmab is the creator of a number of authorized antibody therapeutics that are promoted by its associates. The company aims to build, establish and commercialize differentiated therapies by leveraging subsequent-generation antibody technologies, experience in antibody biology, translational study and facts sciences and strategic partnerships. To generate novel therapies, Genmab makes use of its next-technology antibody technologies, which are the result of its collaborative corporation tradition and a deep passion for innovation. Genmab’s proprietary pipeline is composed of modified antibody candidates, together with bispecific T-mobile engagers and future-era immune checkpoint modulators, effector function improved antibodies and antibody-drug conjugates. The organization is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For additional facts, remember to visit Genmab.com. Speak to: Marisol Peron, Senior Vice President, World-wide Investor Relations & CommunicationsT: +1 609 524 0065 E: [email protected] For Investor Relations: Andrew Carlsen, Senior Director, Head of Investor RelationsT: +45 3377 9558 E: [email protected] This Media Release contains ahead searching statements. The terms “believe”, “expect”, “anticipate”, “intend” and “plan” and identical expressions recognize forward searching statements. Actual benefits or performance may possibly differ materially from any potential results or overall performance expressed or implied by these kinds of statements. The critical factors that could induce our real benefits or performance to differ materially incorporate, among the many others, risks associated with pre-scientific and scientific improvement of goods, uncertainties linked to the consequence and perform of medical trials including unexpected security challenges, uncertainties associated to solution production, the lack of market acceptance of our products, our incapability to manage growth, the competitive natural environment in relation to our enterprise location and markets, our incapability to catch the attention of and keep suitably experienced staff, the unenforceability or lack of safety of our patents and proprietary legal rights, our associations with affiliated entities, variations and developments in technology which may well render our goods or systems obsolete, and other variables. For a further more dialogue of these challenges, be sure to refer to the threat administration sections in Genmab’s most recent economic reports, which are available on www.genmab.com and the threat elements bundled in Genmab’s most modern Annual Report on Form 20-F and other filings with the U.S. Securities and Trade Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise ahead searching statements in this Media Launch nor to affirm this sort of statements to replicate subsequent activities or situation soon after the date made or in relation to true success, until expected by law. Genmab A/S and/or its subsidiaries very own the adhering to trademarks: Genmab® the Y-shaped Genmab logo® Genmab in mixture with the Y-shaped Genmab logo® HuMax® DuoBody® DuoBody in blend with the DuoBody logo® HexaBody® HexaBody in blend with the HexaBody logo® DuoHexaBody® HexElect® and UniBody®. 1Engelbert et al. “DuoBody-CD3xCD20 induces strong T-mobile-mediated killing of malignant B cells in preclinical types and presents chances for subcutaneous dosing.” EBioMedicine. 2020 Feb52: 102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23. PMID: 31981978 PMCID: PMC6992935.2Rafiq, Sarwish, et al. “Comparative Evaluation of Clinically Used CD20-Directed Antibodies in Long-term Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Attributes.” Journal of Immunology (Baltimore, Md. 1950), U.S. Nationwide Library of Medication, 15 Mar. 2013, www.ncbi.nlm.nih.gov/pmc/article content/PMC3631574/.3Singh, Vijay, et al. “Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface area: On the lookout to Boost Immunotherapy Reaction.” Journal of Cancer Science & Remedy, U.S. Countrywide Library of Drugs, Nov. 2015, www.ncbi.nlm.nih.gov/pmc/content/PMC4939752/. Media Release no. 03CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark Attachment 100321_i03_AACR Curtain Raiser
